Home  /  Resource Library  /  Combination of Ibrutinib with Rituximab (IR) in Previously Untreated Older Patients with Mantle Cell Lymphoma (MCL) – a Phase II Clinical Trial

Combination of Ibrutinib with Rituximab (IR) in Previously Untreated Older Patients with Mantle Cell Lymphoma (MCL) – a Phase II Clinical Trial

ASH 2020: Results of a phase II study examining ibrutinib combined with rituximab for first line treatment of mantle cell lymphoma.